Gene · 2395
Papers2,919
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 2,919
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
Generation and characterization of iPSC lines from Friedreich's ataxia patient (FRDA) with GAA.TTC repeat expansion in the Frataxin (FXN) gene's first intron (IGIBi016-A) and a non-FRDA healthy control individual (IGIBi017-A). | Stem Cell Res | 2024 | 38484450 | PubTator, text mining | PubMed |
| Targeting mitochondrial bioenergetics by combination treatment with imatinib and dichloroacetate in human erythroleukemic K‑562 and colorectal HCT‑116 cancer cells. | Int J Oncol | 2024 | 38426621 | PubTator, text mining | PubMed |
| Gene editing improves endoplasmic reticulum-mitochondrial contacts and unfolded protein response in Friedreich's ataxia iPSC-derived neurons. | Front Pharmacol | 2024 | 38420191 | PubTator, text mining | PubMed |
| Phenotypic variation of FXN compound heterozygotes in a Friedreich ataxia cohort. | Ann Clin Transl Neurol | 2024 | 38396238 | PubTator, text mining | PubMed |
| Emerging antioxidant therapies in Friedreich's ataxia. | Front Pharmacol | 2024 | 38379897 | PubTator, text mining | PubMed |
| Generation of two human induced pluripotent stem cell lines, IGIBi012-A and IGIBi013-A from Friedreich's ataxia (FRDA) patients with homozygous GAA repeat expansion in FXN gene. | Stem Cell Res | 2024 | 38367363 | PubTator, text mining | PubMed |
| AAV8 gene therapy reverses cardiac pathology and prevents early mortality in a mouse model of Friedreich's ataxia. | Mol Ther Methods Clin Dev | 2024 | 38352270 | PubTator, text mining | PubMed |
| Searching for Frataxin Function: Exploring the Analogy with Nqo15, the Frataxin-like Protein of Respiratory Complex I from Thermus thermophilus. | Int J Mol Sci | 2024 | 38339189 | PubTator, text mining | PubMed |
Absence of functional deficits in rats following systemic administration of an AAV9 vector despite moderate peripheral nerve and dorsal root ganglia findings: A clinically silent peripheral neuropathy. | Neurotoxicology | 2024 | 38316190 | PubTator, text mining | PubMed |
| Safety, pharmacokinetics, and pharmacodynamics of nomlabofusp (CTI-1601) in Friedreich's ataxia. | Ann Clin Transl Neurol | 2024 | 38311797 | PubTator, text mining | PubMed |
| The fragile X locus is prone to spontaneous DNA damage that is preferentially repaired by nonhomologous end-joining to preserve genome integrity. | iScience | 2024 | 38303711 | PubTator, text mining | PubMed |
| RExPRT: a machine learning tool to predict pathogenicity of tandem repeat loci. | Genome Biol | 2024 | 38297326 | PubTator, text mining | PubMed |
| Editorial: Computational and experimental protein variant interpretation in the era of precision medicine. | Front Mol Biosci | 2024 | 38293601 | PubTator, text mining | PubMed |
| Correction: Human frataxin, the Friedreich ataxia deficient protein, interacts with mitochondrial respiratory chain. | Cell Death Dis | 2024 | 38287008 | PubTator, text mining | PubMed |
| Spinocerebellar ataxia 27B: A novel, frequent and potentially treatable ataxia. | Clin Transl Med | 2024 | 38279833 | PubTator, text mining | PubMed |
| Omaveloxolone: a groundbreaking milestone as the first FDA-approved drug for Friedreich ataxia. | Trends Mol Med | 2024 | 38272714 | PubTator, text mining | PubMed |
| Protective effect of FXN overexpression on ferroptosis in L-Glu-induced SH-SY5Y cells. | Acta Histochem | 2024 | 38266318 | PubTator, text mining | PubMed |
| Perspectives of the Friedreich ataxia community on gene therapy clinical trials. | Mol Ther Methods Clin Dev | 2024 | 38261944 | PubTator, text mining | PubMed |
| Reanalysis of Trio Whole-Genome Sequencing Data Doubles the Yield in Autism Spectrum Disorder: De Novo Variants Present in Half. | Int J Mol Sci | 2024 | 38256266 | PubTator, text mining | PubMed |
| Role of miRNA in Cardiovascular Diseases in Children-Systematic Review. | Int J Mol Sci | 2024 | 38256030 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2395/papers?page=9